Post-displacement mental health among Syrian refugees: A systematic review and meta-analysis comparing Middle Eastern and European host contexts across time.

J Affect DisordMay 14, 2026 (epub)
Clinical ResearchPsychiatry

Emre Han Alpay

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated PTSD, depression, and anxiety among adult Syrian refugees in Middle Eastern and European contexts, synthesizing data from 23 studies. The pooled PTSD prevalence was 32.4%, with no significant differences across early (32.2%) and later periods (32.7%) or between regions (30.5% in Middle Eastern countries vs 34.6% in Europe).

Key findings

  • Pooled PTSD prevalence among Syrian refugees was 32.4% based on 19 studies.
  • No significant difference in PTSD prevalence between early (32.2%) and later periods (32.7%).
  • Depression was generally higher in Middle Eastern samples compared to European contexts.
  • Anxiety prevalence showed greater variability in European settings.

Why it matters

Understanding the mental health burden among Syrian refugees is crucial for developing effective interventions. The consistent prevalence of PTSD, depression, and anxiety highlights the need for targeted mental health support across different host contexts.

What to keep in mind

The limited number of studies may have restricted the statistical power to detect moderation effects.

Source

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.